➡️ Take a look at highlights from #ACR26! 💜 Our team shared important #lupus research findings and connected with researchers, healthcare professionals and advocates to discuss the future of lupus care.
Explore our recap blog: https://t.co/SX7cE1bEkb
Mckenna Bowes, a medical student and #lupuswarrior, spoke at #ACR26 opening session and presented a poster looking for differences among children with lupus who had seizures at baseline and those that didn’t using the @carrainc registry. Love seeing research on #npsle. #LADAorg
AI, health inequalities and EU policy were on the agenda at EULAR PARE Conference in Brussels.
Proud to take part, with @Jeanette_Lupus, Chair of the Lupus Europe Board, presenting #LupusGPT & the role of patient organisations in shaping responsible AI.
Thanks @eular_org PARE!
CAR-T therapy for autoimmune diseases: Are we ready?
Dr. George Tsokos, Chief of Rheumatology at BIDMC, presented the “Not Yet” perspective at #ACR26, highlighting the promise, pitfalls, and risks of premature enthusiasm for CAR-T therapy in autoimmunity.
Thanks to our friends at @IAFaccess for providing this patient-reviewed product. I’ve already reached out for info to purchase the purple 💜 for home infusion. #lupus@LADAOrg
Huge thanks to Spongies for being such an amazing partner! 🙌
Our Champion Nya tested their products, and she loved them. We’re so excited to keep highlighting infusion-related products that genuinely support our community.
Are you at the #ACR26? Come and visit our poster on predictors of flares after achieving drug-free remission in the #SLICC cohort by @bhrasco@GEAS_Peru
Treasury's proposed COINS Act rule would cut U.S. companies off from biotech research abroad, and from breakthroughs people with lupus are counting on. National security matters, but medical R&D isn't a threat. It's hope. Protect Americans’ access to cures.
At #ACR26 with @LADAOrg and got to meet @SarahSisbot and learn about how she correlated her steps taken with her CRP levels. Wonderful to connect with other patient advocates and hear their stories represented. #LADAorg
About 12% of Americans have T2 #diabetes, increasing the risk of developing #cancer and cardiovascular disease. US patients have earlier access to life-extending treatments than in other countries. Yet #MFN threatens that access. https://t.co/Fs1HUXD8Aq #NationalDiabetesMonth
💙 UMass Rheumatology representing at #ACR26!
Great to see our team together, sharing research, exchanging ideas, and connecting with colleagues from across the rheumatology community!
Proud of our amazing team! 👏
#UMassRheum#UMassLupus
A lab test that stresses a patient’s own immune cells may predict who will respond to TNF inhibitors for psoriatic arthritis and IBD. Early data from @NYULangone at #ACR26. ⤵️
Same lupus. Different immune biology.
Beyond anti-dsDNA and complement—#ACR26 insights:
• Tph cells and atypical B cells expand in SLE, linking T–B cell activation with flares.
• Blood profiling identifies 3 lupus nephritis groups: immunologically inactive, IFN-high and cytotoxic T-cell dominant—with differing renal pathology and treatment responses.
• IFN signatures/SIGLEC-1 can track pathway suppression after anifrolumab.
The next frontier: matching treatment to immune biology. Promising; biomarker-guided prescribing still needs validation.
Credit: Dr Deepak Rao
#ACRAmbassador #Lupus #LupusNephritis #PrecisionMedicine
Happening now at #ACR26! 🔬
Our BIDMC Rheumatology fellow Dr. Ryan Payne is presenting his research on treatment patterns, hematologic response, and glucocorticoid exposure in SLE-associated hemolytic anemia!
📍 Poster 0250 | Hall WB1&2
Stop by and say hello! 👏